This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Author notes
David Ernst and Diana Mackie are members of McKinsey & Company, Inc., an international management consulting firm. Mr. Ernst, an associate in McKinsey's office at 1700 Pennsylvania Ave., N.W., Washington, DC, specializes in financial markets and international business. Ms. Mackie, a principal in McKinsey's New York office, works actively with biotechnology and pharmaceutical companies worldwide. The authors wish to acknowledge Leslie Goldwater of McKinsey for her editorial contributions.
Rights and permissions
About this article
Cite this article
Ernst, D., Mackie, D. Fighting the Financing Frenzy: What Next for Biotechnology Companies?. Nat Biotechnol 6, 495–501 (1988). https://doi.org/10.1038/nbt0588-495
Issue Date:
DOI: https://doi.org/10.1038/nbt0588-495
